Therapeutic Response

HER2-negative and PD-L1 (CPS) >= 10 status confers therapeutic sensitivity to Fluorouracil in combination with Oxaliplatin and Pembrolizumab in patients with Adenocarcinoma of the Gastroesophageal Junction.

Statements

Source and description

Pembrolizumab and FOLFOX-6 Modified Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy for for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable or metastatic carcinoma of the oesophagus or HER2-negative gastro-osophageal junction adenocarcinoma whose tumors express PD-L1 with CPS >= 10.